Cryoport's FY25 Revenue Jumps 12%, Exceeding Guidance, Driven by Life Sciences Growth
CYRX sits 97% above its 52-week low of $4.58 on elevated volume (2.0× avg).
Summary
Cryoport reported a 12% year-over-year increase in FY25 revenue, reaching $172.5 million, which exceeded its own guidance, primarily driven by strong growth in its life sciences services segment. The company also announced a strategic partnership with DHL to enhance its global presence and provided positive full-year 2026 revenue guidance of $190 million to $194 million. This update offers a more comprehensive view of Cryoport's performance and outlook, complementing the earlier report of a Q4 loss per share. The strong top-line growth, exceeding expectations, and the new partnership are material positives for the company's operational trajectory and future market position. Traders will now focus on the successful integration of the DHL partnership and the company's progress towards its 2026 financial targets.
At the time of this announcement, CYRX was trading at $9.00 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $425.1M. The 52-week trading range was $4.58 to $11.45. This news item was assessed with positive market sentiment and an importance score of 8 out of 10. Source: Reuters.